Clinical Trial Update: Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS) [Phase 3]

View source ↗

Summary

The Phase 3 study of ixekizumab in active ankylosing spondylitis has been withdrawn. This trial has been removed from the study portfolio.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Ixekizumab (ixekizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Spondylitis, Ankylosing | Phase 3 | Status: WITHDRAWN